Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divesiran in Thalassemia and Low-Risk MDS
NCT04718844Phase 1Completed
- Sponsor
- Silence Therapeutics
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
Phase 1, randomised, single-blind trial of SLN124 in alpha thalassemia, beta thalassemia and myelodysplastic syndrome (MDS) (12 arms), sponsored by Silence Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at Day 140. Started Apr 2021; status: completed.
02
Drugs
SLN124
03
Conditions
alpha thalassemiabeta thalassemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04718844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718844.